Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age

Donald Hurley, Carl Griffin, Mariano Young, Daniel A Scott, Michael W Pride, Ingrid L Scully, John Ginis, Joseph Severs, Kathrin U Jansen, William C Gruber, Wendy Watson, Donald Hurley, Carl Griffin, Mariano Young, Daniel A Scott, Michael W Pride, Ingrid L Scully, John Ginis, Joseph Severs, Kathrin U Jansen, William C Gruber, Wendy Watson

Abstract

Background: Pneumococcal conjugate vaccines (PCVs) have significantly decreased pneumococcal disease worldwide; however, expanding serotype coverage may further reduce disease burden. A 20-valent PCV (PCV20) containing capsular polysaccharide conjugates of serotypes present in the 13-valent PCV (PCV13) and 7 new serotypes (8, 10A, 11A, 12F, 15B, 22F, and 33F) is currently in development. This phase 2 study evaluated safety, tolerability, and immunogenicity of PCV20 in adults without prior pneumococcal vaccination.

Methods: In this randomized, active-controlled, double-blinded trial, 444 adults 60 through 64 years of age were randomized to receive either a single dose of PCV20 followed 1 month later by saline placebo or a single dose of PCV13 followed 1 month later by 23-valent polysaccharide vaccine. Local injection site reactions, select systemic symptoms, and adverse events (AEs) were recorded. Immunogenicity was assessed by measuring serotype-specific opsonophagocytic activity (OPA) titers before and approximately 1 month after each vaccination.

Results: Local reaction and systemic event rates were similar after vaccination with PCV20 or PCV13; no serious vaccine-related AEs were reported. In the PCV20 group, functional immune responses as measured by OPA were robust for all 20 serotypes included in the vaccine, with geometric mean fold rises from baseline ranging from 6.0 to 113.4.

Conclusions: PCV20 was well tolerated in adults 60 to 64 years of age, with a safety profile consistent with historical experience of PCVs in this age group. Substantial OPA responses were elicited against all serotypes. Results demonstrate the potential for PCV20 to expand pneumococcal disease protection.

Clinical trials registration: NCT03313037.

Keywords: Streptococcus pneumoniae; 20-valent pneumococcal conjugate vaccine; adult; clinical trial; immunogenicity and safety.

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.

Figures

Figure 1.
Figure 1.
Study design. Immune responses measured at 12 months following vaccination 1 are not reported here. Abbreviations: PCV13, 13-valent pneumococcal conjugate vaccine; PCV20, 20-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine.
Figure 2.
Figure 2.
Subject disposition. Abbreviations: PCV13, 13-valent pneumococcal conjugate vaccine; PCV20, 20-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine.
Figure 3.
Figure 3.
Prompted reactogenicity events including (A) local reactions within 10 days of vaccination, and (B) systemic events within 7 days of vaccination. The single report of fever is not included. Abbreviations: PCV13, 13-valent pneumococcal conjugate vaccine; PCV20, 20-valent pneumococcal conjugate vaccine.
Figure 4.
Figure 4.
OPA (A) GMTs and (B) GMFRs for the PCV13 serotypes before and 1 month after vaccination. LLOQs for individual serotypes were as follows: serotype 1, 18; serotype 3, 12; serotype 4, 21; serotype 5, 29; serotype 6A, 37; serotype 6B, 43; serotype 7F, 113; serotype 9V, 141; serotype 14, 35; serotype 18C, 31; serotype 19A, 18; serotype 19F, 48; serotype 23F, 13. Abbreviations: GMFR, geometric mean fold rise; GMT, geometric mean titer; LLOQ, lower limit of quantitation; OPA, opsonophagocytic activity; PCV13, 13-valent pneumococcal conjugate vaccine; PCV20, 20-valent pneumococcal conjugate vaccine.
Figure 5.
Figure 5.
OPA (A) GMTs and (B) GMFRs for the 7 additional serotypes before and 1 month after vaccination. LLOQs for individual serotypes were as follows: serotype 8, 16; serotype 10A, 14; serotype 11A, 32; serotype 12F, 51; serotype 15B, 36; serotype 22F, 28; serotype 33F, 49. Abbreviations: CI, confidence interval; GMFR, geometric mean fold rise; GMT, geometric mean titer; LLOQ, lower limit of quantitation; OPA, opsonophagocytic activity; PCV20, 20-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine.

References

    1. World Health Organization. Pneumococcal vaccines WHO position paper 2012. Wkly Epidemiol Rec 2012; 87:129–44.
    1. Blasi F, Mantero M, Santus P, Tarsia P. Understanding the burden of pneumococcal disease in adults. Clin Microbiol Infect 2012; 18:7–14.
    1. Drijkoningen JJ, Rohde GG. Pneumococcal infection in adults: burden of disease. Clin Microbiol Infect 2014; 20:45–51.
    1. Zhang D, Petigara T, Yang X. Clinical and economic burden of pneumococcal disease in US adults aged 19–64 years with chronic or immunocompromising diseases: an observational database study. BMC Infect Dis 2018; 18:436.
    1. Brueggemann AB, Griffiths DT, Meats E, Peto T, Crook DW, Spratt BG. Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential. J Infect Dis 2003; 187:1424–32.
    1. World Health Organization. WHO vaccine-preventable diseases: monitoring system. 2019 global summary. Available at: . Accessed 13 January 2020.
    1. Matanock A, Lee G, Gierke R, Kobayashi M, Leidner A, Pilishvili T. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2019; 68:1069–75.
    1. Clutterbuck EA, Lazarus R, Yu LM, et al. . Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis 2012; 205:1408–16.
    1. Bonten MJ, Huijts SM, Bolkenbaas M, et al. . Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015; 372:1114–25.
    1. Frenck RW Jr, Fiquet A, Gurtman A, et al. ; B1851020 Study Group . Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older. Vaccine 2016; 34:3454–62.
    1. Cohen R, Cohen JF, Chalumeau M, Levy C. Impact of pneumococcal conjugate vaccines for children in high- and non-high-income countries. Expert Rev Vaccines 2017; 16:625–40.
    1. Moore MR, Link-Gelles R, Schaffner W, et al. . Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis 2015; 15:301–9.
    1. Tomczyk S, Lynfield R, Schaffner W, et al. . Prevention of antibiotic-nonsusceptible invasive pneumococcal disease with the 13-valent pneumococcal conjugate vaccine. Clin Infect Dis 2016; 62:1119–25.
    1. Vadlamudi NK, Chen A, Marra F. Impact of the 13-valent pneumococcal conjugate vaccine among adults: a systematic review and meta-analysis. Clin Infect Dis 2019; 69:34–49.
    1. Pilishvili T, Lexau C, Farley MM, et al. ; Active Bacterial Core Surveillance/Emerging Infections Program Network . Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201:32–41.
    1. Hausdorff WP, Hanage WP. Interim results of an ecological experiment–conjugate vaccination against the pneumococcus and serotype replacement. Hum Vaccin Immunother 2016; 12:358–74.
    1. Metcalf BJ, Gertz RE Jr., Gladstone RA, et al. . Strain features and distributions in pneumococci from children with invasive disease before and after 13-valent conjugate vaccine implementation in the USA. Clin Microbiol Infect 2016; 22:60.e9–60.e29.
    1. Wantuch PL, Avci FY. Invasive pneumococcal disease in relation to vaccine type serotypes. Hum Vaccin Immunother 2019; 15:874–5.
    1. Isturiz RE, Ramirez J, Self WH, et al. . Pneumococcal epidemiology among US adults hospitalized for community-acquired pneumonia. Vaccine 2019; 37:3352–61.
    1. Balsells E, Guillot L, Nair H, Kyaw MH. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: a systematic review and meta-analysis. PLoS One 2017; 12:e0177113.
    1. Cui YA, Patel H, O’Neil WM, Li S, Saddier P. Pneumococcal serotype distribution: a snapshot of recent data in pediatric and adult populations around the world. Hum Vaccin Immunother 2017; 13:1–13.
    1. Wroe PC, Lee GM, Finkelstein JA, et al. . Pneumococcal carriage and antibiotic resistance in young children before 13-valent conjugate vaccine. Pediatr Infect Dis J 2012; 31:249–54.
    1. Yahiaoui RY, Bootsma HJ, den Heijer CDJ, et al. . Distribution of serotypes and patterns of antimicrobial resistance among commensal Streptococcus pneumoniae in nine European countries. BMC Infect Dis 2018; 18:440.
    1. Harboe ZB, Thomsen RW, Riis A, et al. . Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med 2009; 6:e1000081.
    1. Pneumovax® 23 (pneumococcal vaccine polyvalent). Whitehouse Station, NJ: Full Prescribing Information, Merck & Co., Inc., 2015.
    1. Thompson A, Lamberth E, Severs J, et al. . Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults. Vaccine 2019; 37:6201–7.
    1. Cooper D, Yu X, Sidhu M, Nahm MH, Fernsten P, Jansen KU. The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A. Vaccine 2011; 29:7207–11.
    1. CDC. Pneumococcal disease. Available at: . Accessed 4 December 2019.
    1. Musher DM, Manof SB, Liss C, et al. . Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. J Infect Dis 2010; 201:516–24.
    1. Jackson LA, Gurtman A, Rice K, et al. . Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 2013; 31:3585–93.
    1. Jackson LA, Gurtman A, van Cleeff M, et al. . Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine 2013; 31:3577–84.
    1. Greenberg RN, Gurtman A, Frenck RW, et al. . Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60–64 years of age. Vaccine 2014; 32:2364–74.
    1. Shiramoto M, Hanada R, Juergens C, et al. . Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults. Hum Vaccin Immunother 2015; 11:2198–206.
    1. Juergens C, de Villiers PJ, Moodley K, et al. . Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults: a randomized open-label trial. Hum Vaccin Immunother 2014; 10:1343–53.
    1. Durando P, Rosselli R, Cremonesi I, et al. . Safety and tolerability of 13-valent pneumococcal conjugate vaccine in the elderly. Hum Vaccin Immunother 2015; 11:172–7.
    1. Jackson LA, Gurtman A, van Cleeff M, et al. . Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine 2013; 31:3594–602.
    1. Jackson LA, Neuzil KM, Whitney CG, et al. . Safety of varying dosages of 7-valent pneumococcal protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 2005; 23:3697–703.
    1. Song JY, Moseley MA, Burton RL, Nahm MH. Pneumococcal vaccine and opsonic pneumococcal antibody. J Infect Chemother 2013; 19:412–25.
    1. Pfizer Inc. Pfizer granted FDA breakthrough therapy designation for 20-valent pneumococcal conjugate vaccine for the prevention of invasive disease and pneumonia in adults aged 18 years and older. Available at: . Accessed 15 May 2019.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit